Total Payments
$7,767
2024 Payments
$1,000
Companies
10
Transactions
30
Medicare Patients
470
Medicare Billing
$68,674
Payment Breakdown by Category
Consulting$5,370 (69.1%)
Food & Beverage$1,374 (17.7%)
Travel$937.65 (12.1%)
Education$85.03 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,370 | 2 | 69.1% |
| Food and Beverage | $1,374 | 22 | 17.7% |
| Travel and Lodging | $937.65 | 3 | 12.1% |
| Education | $85.03 | 3 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $5,786 | 6 | $0 (2020) |
| PFIZER INC. | $1,015 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $369.81 | 8 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $226.40 | 3 | $0 (2019) |
| CSL Behring | $180.03 | 3 | $0 (2021) |
| GENZYME CORPORATION | $67.26 | 3 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $63.50 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $24.80 | 1 | $0 (2018) |
| OptiNose US, Inc. | $18.16 | 1 | $0 (2019) |
| Shire North American Group Inc | $15.56 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,000 | 1 | PFIZER INC. ($1,000) |
| 2023 | $15.27 | 1 | PFIZER INC. ($15.27) |
| 2022 | $77.45 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($63.50) |
| 2021 | $69.76 | 2 | CSL Behring ($69.76) |
| 2020 | $5,812 | 7 | Genentech, Inc. ($5,786) |
| 2019 | $633.91 | 13 | GlaxoSmithKline, LLC. ($329.96) |
| 2018 | $158.50 | 3 | CSL Behring ($110.27) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/30/2024 | PFIZER INC. | PAXLOVID (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 04/05/2023 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 09/12/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: IMMUNOLOGY | ||||||
| 08/03/2022 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $32.98 | General |
| Category: IMMUNOLOGY | ||||||
| 04/26/2022 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Food and Beverage | In-kind items and services | $30.52 | General |
| Category: GENETIC DISEASE | ||||||
| 09/16/2021 | CSL Behring | Hizentra (Biological) | Education | In-kind items and services | $51.76 | General |
| Category: Immunology | ||||||
| 04/14/2021 | CSL Behring | Hizentra (Biological) | Education | In-kind items and services | $18.00 | General |
| Category: Immunology | ||||||
| 02/19/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $25.90 | General |
| Category: RESPIRATORY | ||||||
| 01/25/2020 | Genentech, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $353.42 | General |
| Category: Immunology | ||||||
| 01/24/2020 | Genentech, Inc. | Xolair (Biological) | Consulting Fee | Cash or cash equivalent | $4,370.00 | General |
| Category: Immunology | ||||||
| 01/24/2020 | Genentech, Inc. | Xolair (Biological) | Travel and Lodging | In-kind items and services | $555.50 | General |
| Category: Immunology | ||||||
| 01/24/2020 | Genentech, Inc. | Xolair (Biological) | Travel and Lodging | In-kind items and services | $351.41 | General |
| Category: Immunology | ||||||
| 01/24/2020 | Genentech, Inc. | Xolair (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Immunology | ||||||
| 01/24/2020 | Genentech, Inc. | Xolair (Biological) | Travel and Lodging | Cash or cash equivalent | $30.74 | General |
| Category: Immunology | ||||||
| 12/18/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $31.39 | General |
| Category: RESPIRATORY | ||||||
| 12/04/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2019 | Teva Pharmaceuticals USA, Inc. | CINQAIR (Biological) | Food and Beverage | In-kind items and services | $82.95 | General |
| Category: Respiratory | ||||||
| 10/23/2019 | Shire North American Group Inc | CINRYZE (Drug) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2019 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 09/12/2019 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $109.23 | General |
| Category: RESPIRATORY | ||||||
| 08/07/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $29.29 | General |
| Category: RESPIRATORY | ||||||
| 07/24/2019 | GENZYME CORPORATION | DUPIXENT (Drug), DUPIXENT | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: IMMUNOLOGY | ||||||
| 07/03/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: RESPIRATORY | ||||||
| 06/27/2019 | Teva Pharmaceuticals USA, Inc. | CINQAIR (Biological) | Food and Beverage | In-kind items and services | $105.00 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 77 | 95 | $70,887 | $11,356 |
| 2022 | 5 | 167 | 240 | $171,473 | $27,393 |
| 2021 | 3 | 127 | 175 | $119,557 | $19,001 |
| 2020 | 5 | 99 | 113 | $85,211 | $10,923 |
Total Patients
470
Total Services
623
Medicare Billing
$68,674
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 66 | 82 | $63,386 | $10,216 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 13 | $7,501 | $1,140 | 15.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 92 | 161 | $124,453 | $20,121 | 16.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $28,210 | $3,677 | 13.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 24 | $13,848 | $2,071 | 15.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 13 | 14 | $2,562 | $1,147 | 44.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 15 | 15 | $2,400 | $376.68 | 15.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 61 | 89 | $68,797 | $11,119 | 16.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 40 | 40 | $43,400 | $6,577 | 15.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 26 | 46 | $7,360 | $1,305 | 17.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 38 | 48 | $37,104 | $4,314 | 11.6% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 22 | 25 | $14,291 | $2,480 | 17.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $13,020 | $1,719 | 13.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 16 | 16 | $13,872 | $1,626 | 11.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 11 | 12 | $6,924 | $783.49 | 11.3% |
About Dr. Michele Pham, M.D
Dr. Michele Pham, M.D is a Allergy & Immunology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2013. The National Provider Identifier (NPI) number assigned to this provider is 1194169300.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michele Pham, M.D has received a total of $7,767 in payments from pharmaceutical and medical device companies, with $1,000 received in 2024. These payments were reported across 30 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($5,370).
As a Medicare-enrolled provider, Pham has provided services to 470 Medicare beneficiaries, totaling 623 services with total Medicare billing of $68,674. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location San Francisco, CA
- Active Since 04/18/2013
- Last Updated 11/08/2018
- Taxonomy Code 207RA0201X
- Entity Type Individual
- NPI Number 1194169300
Products in Payments
- Xolair (Biological) $5,786
- PAXLOVID (Drug) $1,000
- NUCALA (Biological) $260.58
- CINQAIR (Biological) $226.40
- Hizentra (Biological) $180.03
- TRELEGY ELLIPTA (Drug) $109.23
- DUPIXENT (Drug) $67.26
- HYQVIA (Biological) $32.98
- TAKHZYRO (Biological) $30.52
- FASENRA (Drug) $24.80
- Xhance (Drug) $18.16
- CINRYZE (Drug) $15.56
- CIBINQO (Drug) $15.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in San Francisco
Dr. Daniel Adelman, M.d, M.D
Allergy & Immunology — Payments: $93,363
Allergy & Immunology $93,363
Lulu Tsao
Allergy & Immunology — Payments: $10,381
Allergy & Immunology $10,381
Dr. Jeffrey Davidson, M.d, M.D
Allergy & Immunology — Payments: $9,015
Allergy & Immunology $9,015
Dr. Jonathan Witonsky, M.d, M.D
Allergy & Immunology — Payments: $7,779
Allergy & Immunology $7,779
Monica Tang
Allergy & Immunology — Payments: $7,663
Allergy & Immunology $7,663
Anna Lang
Allergy & Immunology — Payments: $4,226
Allergy & Immunology $4,226